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Susceptibility to herpes simplex virus type 1 (HSV-1) encephalitis (HSE-1) in otherwise
healthy individuals, in the course of primary infection, can be caused by single-gene inborn
errors of Toll-like receptor 3 (TLR3) dependent, interferon (IFN)-α/β-mediated immunity,1,2
or by single-gene inborn errors of snoRNA31.3 These variations underlie infections of the
forebrain, whereas mutations of DBR1 underlie infections of the brainstem.3 HSV-2 enceph-
alitis (HSE-2) is typically observed in neonates, albeit also rarely in older children and adults.4
Its manifestations include altered level of consciousness, cranial neuropathies or more extensive
brainstem encephalitis, hemiparesis, hemisensory loss, and permanent neurologic deficit.4 MRI
in HSE-2 may show normal findings, nonspecific white matter, orbitofrontal, mesial temporal
lobe, or brainstem lesions. Inborn errors of immunity underlying HSE-2 have not been
described.
A 40-year-old previously healthy woman had suffered from headache and fever of up to 38°C for
6 days when she suddenly developed aphasia. At hospital admission, her body temperature was
37.1°C, blood pressure was 138/90 mm Hg, and vital signs were normal. She was fully con-
scious and co-operative but aphasic. Her blood hemoglobin level was low (107 g/L, normal
range 117–155 g/L), with normal C-reactive protein level, blood white cell and thrombocyte
counts, and negative blood and urine cultures. Acute phase brain CT, CT angiography and
contrast enhanced MRI were unremarkable. CSF showed elevated mononuclear (98%) white
cell count (166 × 106/L; normal <3 × 106/L) and high protein concentration (1,192 mg/L;
normal range 150–500mg/L). CSF was positive for HSV-2 and negative for HSV-1 nucleic acid
by automated and accredited real-time PCR (artus HSV-1/2 PCR Kits; QIAsymphony SP,
Rotor-Gene Q, Qiagen, Hilden, Germany). EEG showed left focal frontotemporobasal 2 Hz
slow wave activity consistent with viral encephalitis (figure). She received IV acyclovir for 21
days with improvement in aphasia. Neuropsychological assessment 1 month later revealed poor
word fluency, problems with memory interference, and delayed word list memory. The patient
continued to suffer from lassitude and mild depression at least for over 12 months after the
acute episode. Her presentation was consistent with International the Encephalitis Consortium
diagnostic criteria for encephalitis.5 After the acute episode, she developed frequently recurrent
eczema herpeticum of lower back tested positive for HSV-2 nucleic acid, suggesting recent
primary HSV-2 infection. She did not suffer from genital herpes. This was controlled with
peroral prophylactic valacyclovir 500 mg twice daily.
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The patient was remitted for immunologic evaluation. Family
history was unremarkable; she had no history of general in-
fection susceptibility, autoimmunity, or secondary immuno-
deficiency. Blood white cell and lymphocyte (CD19+ B, CD4+
and CD8+ T, CD16+CD56+ NK) counts and percentages of T
and B lymphocyte subclasses were normal, suggesting normal
maturation. She was positive for anti-HSV2 immunoglobulin G
(IgG) and negative for anti-HSV1 IgG. Whole exome se-
quencing showed a heterozygous rs147431766 TLR3 (chr4:
187005064C>T, ENSG00000164342:ENST00000296795:
exon4:c.C2224T:p.L742F) variant, enriched over 23-fold in
the Finnish compared with non-Finnish Europeans (allele
frequency 0.01621 vs 0.0006819, Genome Aggregation Data-
base; gnomad.broadinstitute.org/). TLR3 p.L742F variant is in
vitro severely hypomorphic based on experiments on TLR3-
deficient P2.1 fibrosarcoma cell line, and the production of
IFN-λ and interleukin-6 in response to TLR3 activation by
poly(I:C) stimulation was impaired in previously tested
SV40 immortalized human skin fibroblasts heterozygous for
this variation.6 She was also found to be positive for TRF1-
interacting nuclear factor 2 (TINF2) variant p.Y312*
(rs201677741) previously associated with Ewing sarcoma.
Pathogenic TINF variants are associated with autosomal
dominant dyskeratosis congenita and pathologic telomere
lengths (OMIM 604319). However, her telomere length
was within the normal interval compared with healthy
controls of similar age. Patient’s father had died of
aggressive cholangiocarcinoma, and her mother has had
one episode of varicella zoster skin infection. TLR3
p.L742F and TINF2 p.Y312* variants were inherited from
the mother. Patient’s sister had suffered from recurrent
laboratory confirmed cutaneous HSV2 infections. Her
targeted testing did not reveal TLR3 p.L742F or TINF2
p.Y312* variants.
Previous evidence shows that inborn errors in TLR3-mediated
immune response may explain HSE-1 in a subset of patients.1–3
Our patient suffered anHSE-2 episode associated with impaired
TLR3-mediated antiviral response. To our knowledge, this is
the first report of a genetic mechanism potentially explaining
HSE-2 in immunocompetent patients. The TLR3 p.L742F
variant found in our patient is enriched in Finnish population;
we can only speculate that this property may associate with
HSV-2 CNS infections in Finland.7 We emphasize that our
report does not prove causality between TLR3 deficiency and
HSE-2 but suggests that TLR3 signaling defects may need to be
contemplated in otherwise healthy HSE-2 patients.
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Figure EEG shows focal left frontotemporobasal 2 Hz slow wave activity consistent with encephalitis diagnosis
Normal background activity and the patient is awake.
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